NCT02731287View on ClinicalTrials.gov

Topical Timolol for Infantile Hemangioma in Early Proliferative Phase

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

March 31, 2017

Conditions
Hemangioma
Interventions
DRUG

Timolol

The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks

DRUG

Placebo

The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks

Trial Locations (2)

41013

Hospital Virgen del Rocío, Seville

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT02731287 - Topical Timolol for Infantile Hemangioma in Early Proliferative Phase | Biotech Hunter | Biotech Hunter